Nutrient-stimulated hormone (NuSH) therapies, including GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists, are now recommended for adults with obesity due to their impactful dual effects on weight loss and cardiovascular risk reduction. With obesity affecting over 40% of U.S. adults, NuSH therapies offer a viable pharmacological alternative to lifestyle modifications and bariatric surgery. Clinical trials have shown significant weight loss results with these agents, alongside cardiovascular benefits, suggesting a need for comprehensive obesity management approaches in clinical practice.

Source: JACC